Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer

Official record

Identifier

NCT07526675

Recruiting locations

country

Egypt

Interventions studied

Bioblation

Lead sponsor

Benha University

Target enrolment

30 participants

Study type

INTERVENTIONAL

Phase

Not applicable

Status

Recruiting

First posted

Apr 13, 2026

Last updated on the registry

Sep 30, 2026

Age

18 Months

Sex

MALE

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Patients with severe Lower Urinary Tract Symptoms (LUTS) meeting the following parameters:

  1. IPSS score \> 20
  2. Uroflowmetry flow rate \< 10 ml/sec
  3. Post-void residual \> 150 cc
* Patients most probably having low to favorable intermediate-risk prostate cancer, defined as:

  1. PSA level between 4 and 20 ng/ml
  2. MP-MRI showing 3 or fewer focal lesions
  3. MP-MRI focal lesions measuring \< 1.5 cm
* International or visiting patients requiring early return to their home country due to professional or personal commitments, provided they can undergo short-term management and follow-up coordination

Exclusion Criteria:

* Patient PSA level \> 20 ng/ml
* More than 3 focal lesions on MP-MRI
* Metastatic prostate cancer
* History of lower urinary tract surgery (e.g., TURP, Laser, urinary diversions, artificial urinary sphincter)
* History of pelvic radiation therapy or radical pelvic surgery

Indexed under

Prostate Cancer